Survival and disease-free survival by breast density and fhenotype in interval breast cancers

Sala i Serra, Maria; Domingo, Laia; Louro, Javier; Torá Rocamora, Isabel, 1979-; Baré, Marisa; Ferrer, Joana; Carmona-Garcia, Maria Carmen; Barata, Teresa; Román, Marta; Macià Guilà, Francesc Assís; Castells, Xavier; CAMISS Study Group

doi:http://dx.doi.org/10.1158/1055-9965.EPI-17-0995

Survival and disease-free survival by breast density and fhenotype in interval breast cancers

Citation

Sala M, Domingo L, Louro J, Torá-Rocamora I, Baré M, Ferrer J. et al. Survival and disease-free survival by breast density and fhenotype in interval breast cancers. Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):908-916. DOI: 10.1158/1055-9965.EPI-17-0995

Abstract

Background: We aimed to evaluate survival and disease-free survival in different subtypes of interval cancers by breast density, taking into account clinical and biological characteristics.Methods: We included 374 invasive breast tumors (195 screen-detected cancers; 179 interval cancers, classified into true interval, false-negatives, occult tumors and minimal-sign cancers) diagnosed in women ages 50-69 years undergoing biennial screening from 2000-2009, followed up to 2014. Breast density was categorized into non-dense (<25% dense tissue) and mixed dense breasts (≥25%). Survival curves were generated by the Kaplan-Meier method and compared by the log-rank test. Cox proportional hazard regression models were computed to estimate the adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs) for death and recurrences by comparing women with interval and true interval cancers versus women with screen-detected cancers, controlling for tumor and patient characteristics. All analyses were stratified by breast density.Results: Interval cancers were detected in younger women, at more advanced stages, in denser breasts and showed a higher proportion of triple-negative cancers, especially among true interval cancers. Women with interval cancer and non-dense breasts had an aHR for death of 3.40 (95% CI, 0.92-12.62). Women with true interval cancers detected in non-dense breasts had the highest adjusted risk of death (aHR, 6.55; 95% CI, 1.37-31.39).Conclusions: Women with true interval cancer in non-dense breasts had a higher risk of death than women with screen-detected cancers.Impact: These results support the advisability of routinely collecting information on breast density, both for further tailoring of screening strategies and as a prognostic factor for diagnosed breast cancers. Cancer Epidemiol Biomarkers Prev; 27(8); 908-16. ©2018 AACR.